<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02950441</url>
  </required_header>
  <id_info>
    <org_study_id>RG_15-152</org_study_id>
    <nct_id>NCT02950441</nct_id>
  </id_info>
  <brief_title>Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype</brief_title>
  <acronym>NADMet</acronym>
  <official_title>Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype (NADMet)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the physiological consequences of elevating Nicotinamide
      Adenine Dinucleotide (NAD+) availability using Nicotinamide Riboside (NR) supplementation in
      skeletal muscle tissue, and examine its effect upon muscle metabolic phenotype.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -NAD+ sensitive metabolic decline in ageing, including sarcopenia, leads to a reduction in
      energy metabolism, contribute to chronic inflammation, disposing individuals to metabolic
      disease and overall decreased later-life health. Prominent metabolic changes include a
      decline in NAD+ content and deterioration in muscle NAD+ mediated signalling and
      mitochondrial function, ultimately compromising skeletal muscle and whole body energy
      homeostasis.

      The most efficient means to boost NAD+ in muscle appears to be oral delivery of NR, and
      participants will be supplemented with 1000mg NR (2x x250mg tablets twice daily) for 3 weeks.

        -  Hypothesis: elevating skeletal muscle NAD+ bioavailability using NR supplementation will
           increase markers of mitochondrial function and that will manifest as a more favourable
           metabolic profile.

        -  Study Setting: the study will be carried out at the NIHR/Wellcome Trust Clinical
           Research Facility, Queen Elizabeth Hospital Birmingham.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mitochondrial function assessment in skeletal muscle using high resolution respirometry</measure>
    <time_frame>Following 3 weeks of NR supplementation</time_frame>
    <description>Mitochondrial function assessment on muscle biopsies using high resolution respirometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal muscle NAD+ levels in vastus lateralis biopsy using targeted metabolomics</measure>
    <time_frame>Following 3 weeks of NR supplementation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in response to oral glucose tolerance test/HOMA-IR</measure>
    <time_frame>Following 3 weeks of NR supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in lipid profile</measure>
    <time_frame>Following 3 weeks of NR supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Arterio-Venous Difference - Tissue-specific metabolite trafficking, oxygen consumption and CO2 production</measure>
    <time_frame>Following 3 weeks of NR supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle biopsy: adaptive expression profile (genomic)</measure>
    <time_frame>Following 3 weeks of NR supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in resting metabolic rate using indirect calorimetry</measure>
    <time_frame>Following 3 weeks of NR supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urine collection - NAD+ metabolomics and changes in steroid ratios using Gas chromatography/ mass spectrometry</measure>
    <time_frame>Following 3 weeks of NR supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength - grip testing</measure>
    <time_frame>Following 3 weeks of NR supplementation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Nicotinamide Riboside</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000mg (2x250mg tablets twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two tablets twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nicotinamide Riboside</intervention_name>
    <arm_group_label>Nicotinamide Riboside</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male sex

          -  Age 70-80 years

          -  BMI 20-30kg/m2

          -  Participants who are able to discontinue aspirin for 3 days prior to the muscle biopsy

          -  Participants who are able to discontinue statins and vitamin D supplements for a week
             before the second visit and for the duration of the study

        Exclusion Criteria:

          -  Serious active medical conditions including inflammatory diseases or malignancies

          -  Significant past medical history including diabetes mellitus, ischaemic heart disease,
             cerebrovascular disease, significant respiratory disease requiring medication,
             epilepsy

          -  High blood pressure (BP&gt;160/100mmHg)

          -  Oral Anticoagulants (like Warfarin, Dabigatran, Rivaroxaban) or Clopidogrel therapy
             which will increase the risk of bruising following a muscle biopsy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gareth Lavery, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Metabolism and Systems Research, University of Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yasir Elhassan, MRCP</last_name>
    <phone>+441214158705</phone>
    <email>y.mohamedelhassan@bham.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gareth Lavery, PhD</last_name>
    <phone>+441214143917</phone>
    <email>g.g.lavery@bham.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasir Elhassan, MRCP</last_name>
      <phone>+441214158705</phone>
      <email>y.mohamedelhassan@bham.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicotinamide Riboside</keyword>
  <keyword>Nicotinamide Adenine Dinucleotide</keyword>
  <keyword>Skeletal muscle</keyword>
  <keyword>Metabolism</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

